| Literature DB >> 25610776 |
Matteo Figini1, Daniel C Alexander2, Veronica Redaelli3, Fabrizio Fasano4, Marina Grisoli5, Giuseppe Baselli6, Pierluigi Gambetti7, Fabrizio Tagliavini3, Alberto Bizzi8.
Abstract
In clinical practice signal hyperintensity in the cortex and/or in the striatum on magnetic resonance (MR) diffusion-weighted images (DWIs) is a marker of sporadic Creutzfeldt-Jakob Disease (sCJD). MR diagnostic accuracy is greater than 90%, but the biophysical mechanisms underpinning the signal abnormality are unknown. The aim of this prospective study is to combine an advanced DWI protocol with new mathematical models of the microstructural changes occurring in prion disease patients to investigate the cause of MR signal alterations. This underpins the later development of more sensitive and specific image-based biomarkers. DWI data with a wide a range of echo times and diffusion weightings were acquired in 15 patients with suspected diagnosis of prion disease and in 4 healthy age-matched subjects. Clinical diagnosis of sCJD was made in nine patients, genetic CJD in one, rapidly progressive encephalopathy in three, and Gerstmann-Sträussler-Scheinker syndrome in two. Data were analysed with two bi-compartment models that represent different hypotheses about the histopathological alterations responsible for the DWI signal hyperintensity. A ROI-based analysis was performed in 13 grey matter areas located in affected and apparently unaffected regions from patients and healthy subjects. We provide for the first time non-invasive estimate of the restricted compartment radius, designed to reflect vacuole size, which is a key discriminator of sCJD subtypes. The estimated vacuole size in DWI hyperintense cortex was in the range between 3 and 10 µm that is compatible with neuropathology measurements. In DWI hyperintense grey matter of sCJD patients the two bi-compartment models outperform the classic mono-exponential ADC model. Both new models show that T2 relaxation times significantly increase, fast and slow diffusivities reduce, and the fraction of the compartment with slow/restricted diffusion increases compared to unaffected grey matter of patients and healthy subjects. Analysis of the raw DWI signal allows us to suggest the following acquisition parameters for optimized detection of CJD lesions: b = 3000 s/mm(2) and TE = 103 ms. In conclusion, these results provide the first in vivo estimate of mean vacuole size, new insight on the mechanisms of DWI signal changes in prionopathies and open the way to designing an optimized acquisition protocol to improve early clinical diagnosis and subtyping of sCJD.Entities:
Keywords: ADC, apparent diffusion coefficient; BIC, Bayesian information criterion; Biophysical models; CJD, Creutzfeldt–Jakob disease; CNR, contrast to noise ratio; Creutzfeldt–Jakob disease; DWI, diffusion weighted imaging; Diffusion MRI; EEG, electroencephalogram; EPI, echo-planar imaging; FOV, field of view; GSS, Gerstmann–Sträussler–Scheinker syndrome; MPRAGE, magnetization-prepared rapid acquisition gradient-echo; PrPC, prion protein cellular; PrPSc, prion protein scrapie; Prion disease; ROI, region of interest; RPE, rapidly progressive encephalopathy; SS-SE, single shot spin-echo; Spongiform degeneration; TE, echo time; TI, inversion time; TR, repetition time; sCJD, sporadic Creutzfeldt–Jakob disease
Mesh:
Year: 2014 PMID: 25610776 PMCID: PMC4300005 DOI: 10.1016/j.nicl.2014.11.017
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Clinical data, MR imaging and laboratory test results for the 15 patients and 4 healthy controls.
| Patient code | Sex | Age at onset (years) | Total disease duration (mos) | Disease duration at MRI (mos) | Clinical findings | PRNP mutation | PRNP codon 129 | 14-3-3 | Tau (pg/ml) | DWI | EEG | Predicted sCJD molecularsubtype | Average Radius in ROI with signal hyperintensity | Average Radius in ROI without signal abnormality | Clinical Diagnosis | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Initial signs | Full stage | |||||||||||||||||||
| Dementia | Cerebellar /visual | Pyramidal/ Extrapyr signs | Behavioural disorder | Mioclonus | ||||||||||||||||
| CJD01 | F | 60 | 14 | 2 | cognitive deficits | 1 | 1 | 0 | 1 | 1 | E200K | MV | ND | ND | 1 | 0 | - | 5,54 | 0,2 | familial CJD |
| CJD02 | M | 61 | 5 | 2 | cognitive deficits | 1 | 1 | 0 | 0 | 0 | 0 | VV | positive | 15432 | 1 | 0 | VV2 | 6,07 | 2,58 | sCJD |
| CJD03 | M | 75 | 7 | 6 | ataxia | 1 | 1 | 1 | 0 | 0 | 0 | MV | ambiguous | 6983 | 1 | 1 | MV2 | 4,13 | 1,84 | sCJD |
| CJD04 | M | 74 | 8 | 7 | parkinsonism | 1 | 0 | 1 | 1 | 1 | 0 | MM | ND | ND | 1 | 1 | MM1 | 4,37 | 3,33 | sCJD |
| CJD05 | F | 55 | 29 | 3 | cognitive deficits | 1 | 0 | 0 | 1 | 0 | 0 | MM | positive | 2100 | 1 | 1 | MM2 | 5,16 | 6,54 | sCJD |
| CJD06 | M | 70 | 24 | 24 | ataxia | 1 | 1 | 1 | 0 | 1 | 0 | VV | positive | 2062 | 1 | 0 | VV2 | 4,87 | 2,62 | sCJD |
| CJD07 | M | 69 | 3 | 2 | cognitive deficits | 1 | 1 | 1 | 1 | 1 | 0 | MV | positive | 2113 | 1 | 1 | MV1 | 4,45 | 1,29 | sCJD |
| CJD08 | F | 65 | 38 | 23 | cognitive deficits | 1 | 0 | 1 | 1 | 0 | 0 | MV | ambiguous | 1648 | 1 | 0 | MV2 | 7,32 | 8,02 | sCJD |
| CJD09 | M | 64 | 17 | 8 | ataxia | 1 | 1 | 0 | 0 | 0 | 0 | MV | positive | 617 | 1 | 0 | MV2 | 5,37 | 6,71 | sCJD |
| CJD10 | F | 73 | 16 | 2 | cognitive deficits | 1 | 0 | 1 | 0 | 1 | 0 | MV | positive | 2390 | 1 | 1 | MV2 | 7,07 | 3,91 | sCJD |
| GSS01 | M | 32 | 45 | 12 | ataxia | 0 | 1 | 0 | 0 | 0 | P102L | MM | negative | 462 | 0 | 0 | - | NA | 1,85 | GSS |
| GSS02 | F | 56 | 33 | 3 | ataxia | 0 | 1 | 0 | 0 | 0 | P102L | MM | ND | ND | 0 | 0 | - | NA | 2,53 | GSS |
| RPE01 | M | 59 | NA | 10 | cognitive deficits | 1 | 0 | 0 | 0 | 0 | 0 | - | negative | 267 | 0 | 0 | - | NA | 3,04 | autoimmune encefalopathy |
| RPE02 | F | 80 | 8 | 5 | ataxia | 0 | 1 | 0 | 0 | 0 | 0 | - | ambiguous | 637 | 0 | 0 | - | NA | 0,86 | paraneoplastic encefalopathy |
| RPE03 | M | 81 | NA | 4 | cognitive deficits | 1 | 0 | 0 | 1 | 0 | 0 | - | - | - | 0 | 0 | - | NA | 2,53 | paraneoplastic encefalopathy |
| HC01 | F | 66 | - | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | - | 0 | - | - | NA | NA | Normal |
| HC02 | M | 59 | - | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | - | 0 | - | - | NA | NA | Normal |
| HC03 | M | 59 | - | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | - | 0 | - | - | NA | NA | Normal |
| HC04 | M | 63 | - | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | - | 0 | - | - | NA | NA | Normal |
The sCJD molecular subtype (MM1, MM2, MV1, MV2, VV2) was assigned to each patient according to the clinical data indicated in this table.
Abbreviations: CJD = Creutzfeldt-Jakob disease; GSS = Gerstmann–Sträussler–Scheinker syndrome; RPE = rapidly progressive encephalopathy; HC = healthy control; F = female; M = male; 1 = positive; 0 = negative; PRNP = PRioN Protein; MM=Methionine-Methionine; MV=Methionine-Valine; VV=Valine-Valine; NA = not applicable; ND = not determined; sCJD = sporadic Creutzfeldt-Jakob disease.
Fig. 1MR images used for clinical diagnosis of sCJD in one patient with sCJD acquired at the level of the basal nuclei and lateral ventricles. Affected (CJD+) regions look bright and are more prominent on DWI with b = 1000 than b = 500, FLAIR and T2WI respectively in this order. Affected regions with decreased diffusivity look darker on ADC maps. Note the asymmetry of signal hyperintensities that in this patient are more extensive in the left cerebral hemisphere than in the right, basal nuclei and thalami.
Fig. 2Raw signal in the different groups. A) Raw signal in the three main groups at each combination of the acquisition parameters. B) Relative difference between the mean signal in each pair of groups at each combination of the acquisition parameters.In both the plots, for any b-value reported on the graph, the TE grows from left to right (see the TE values applied at each b-value in Inline Supplementary Table 1).
Fig. 3Visual assessment of the quality of fit in a representative ROI of a CJD patient. The raw signal (stars) and the signal predicted by each model (solid lines with different colours) are shown for every volume acquired. See Supplementary Table 1 for the acquisition parameters applied.
Mean BIC values for each model in CJD+, CJD− and HC ROIs.
| BIC values | CJD+ | CJD− | HC |
|---|---|---|---|
| Biexponential | 2277 ± 141 (*,#) | 2106 ± 156 (*) | 2022 ± 80 (*) |
| Restricted | 2287 ± 141 (*,#) | 2116 ± 156 (*) | 2031 ± 86 (*) |
| Mono-exponential | 2633 ± 367 (#) | 2305 ± 291 (#) | 2143 ± 163 |
Higher values are associated with worse fitting performances. Values marked with (*) are significantly lower than the mean BIC of the mono-exponential in the same group of ROIs, showing a better fitting performance of the bi-compartment models with respect to the traditional one. Values marked with (#) are significantly higher than the mean BIC of the mono-exponential in the HC group, showing a worse fitting performance with respect to the normal case, probably due to pathological changes not fully explained by the models.
Results of the group analysis. Mean relative difference in each parameter between each group (CJD+, CJD−, RPE or GSS respectively) and the healthy controls.
| CJD+ | CJD- | RPE | GSS | ||
|---|---|---|---|---|---|
| Biexponential | n.s. | n.s. | n.s. | n.s. | |
| + 26% | + 10% | n.s. | n.s. | ||
| -14% | n.s. | n.s. | n.s. | ||
| -37% | n.s. | -20% | n.s. | ||
| + 4% | n.s. | + 9% | n.s. | ||
| Restricted | n.s. | n.s. | n.s. | n.s. | |
| + 18% | + 8% | n.s. | n.s. | ||
| n.s. | + 8% | + 10% | n.s. | ||
| + 46% | + 19% | n.s. | n.s. | ||
| Monoexp | -8% | n.s. | n.s. | n.s. | |
| + 31% | + 12% | + 5% | n.s. | ||
| -20% | n.s. | + 5% | n.s. |
Abbreviations: n.s. = not significant.
Fig. 4Tridimensional representation of the regional dependence of statistical differences in the estimated parameters. A) 3D rendering of the cortical and subcortical areas considered in the ROI-based analysis. B–F) Representation of the statistical significance of the differences between CJD+ and HC for the main parameters: T2 in the mono-exponential models (B) and dF (C) and d (D) in the biexponential model; ADC in the mono-exponential model (E); the volumetric fraction of the spherical restricted compartment in the restricted-diffusion model (F). In each panel the analysed areas without significant differences are in blue, while the areas with statistically significant differences are in yellow (p < 0.05), orange (p < 0.01) or red (p < 0.001).
Fig. 5Estimated radius of the spherical compartment in the different subjects and areas. A) Histogram showing the estimated radius averaged across all the ROIs in each subject. B) Histogram showing the estimated radius averaged across all the CJD+ ROIs in each anatomical area.
Acquisition protocol. The images are acquired with increasing TE values (shown in the first column), and increasing b-values (shown in the following columns) for each TE.
| TE (ms) | b-values (s/mm2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 68 | 0 | 250 | 500 | 800 | 1000 | |||||||||
| 71 | 0 | 250 | 500 | 800 | 1000 | |||||||||
| 77 | 0 | 250 | 500 | 800 | 1000 | 1500 | ||||||||
| 81 | 0 | 250 | 500 | 800 | 1000 | 1500 | 2000 | |||||||
| 89 | 0 | 250 | 500 | 800 | 1000 | 1500 | 2000 | 3000 | ||||||
| 94 | 0 | 250 | 500 | 800 | 1000 | 1500 | 2000 | 3000 | 4000 | |||||
| 99 | 0 | 250 | 500 | 800 | 1000 | 1500 | 2000 | 3000 | 4000 | 5000 | ||||
| 103 | 0 | 250 | 500 | 800 | 1000 | 1500 | 2000 | 3000 | 4000 | 5000 | 6000 | |||
| 107 | 0 | 250 | 500 | 800 | 1000 | 1500 | 2000 | 3000 | 4000 | 5000 | 6000 | 7000 | 8000 | 9000 |
Mean value of each estimated parameter in each anatomical area in the healthy controls.
| Mean values in HC | ACC | PreCu | SFG | aMFG | STG | ITG | SPL | IPL | Occ | Hip | Cau | aPut | DMTh | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biexponential | 832±69 | 1289±50 | 781±101 | 803±104 | 1031±85 | 899±175 | 1495±87 | 1270±48 | 1236±104 | 895±61 | 858±65 | 879±31 | 995±22 | |
| 95±3 | 81±5 | 107±6 | 106±9 | 82±6 | 92±11 | 86±3 | 83±4 | 77±5 | 93±4 | 81±2 | 73±2 | 74±3 | ||
| 1510±227 | 2150±307 | 2070±298 | 2240±267 | 2090±895 | 1720±455 | 2580±279 | 1930±283 | 1560±190 | 1660±1043 | 1040±134 | 1080±157 | 1240±248 | ||
| 236±63 | 358±76 | 364±74 | 393±38 | 290±109 | 263±136 | 372±60 | 341±58 | 178±36 | 109±143 | 51±62 | 29±60 | 62±94 | ||
| 0.622±0.062 | 0.496±0.067 | 0.501±0.062 | 0.484±0.042 | 0.546±0.088 | 0.576±0.130 | 0.554±0.069 | 0.531±0.053 | 0.638±0.040 | 0.732±0.146 | 0.763±0.054 | 0.740±0.068 | 0.732±0.085 | ||
| Restricted | 822±67 | 1248±49 | 766±97 | 786±98 | 1018±87 | 884±169 | 1460±88 | 1237±46 | 1250±139 | 908±61 | 859±62 | 883±26 | 993±22 | |
| 95±3 | 82±5 | 108±6 | 107±9 | 82±6 | 92±11 | 87±3 | 84±4 | 76±7 | 91±5 | 80±2 | 72±3 | 74±3 | ||
| 1157±78 | 1232±34 | 1303±89 | 1354±93 | 1295±26 | 1177±89 | 1559±190 | 1212±90 | 1225±72 | 1326±490 | 992±84 | 1035±77 | 1129±73 | ||
| 0.21±0.06 | 0.83±1.72 | 0.15±0.01 | 0.15±0.02 | 1.86±3.08 | 0.24±0.08 | 3.24±3.39 | 0.21±0.03 | 4.90±3.11 | 3.78±3.32 | 1.46±2.27 | 2.64±2.19 | 1.71±1.79 | ||
| 0.182±0.010 | 0.171±0.013 | 0.188±0.019 | 0.187±0.014 | 0.207±0.031 | 0.186±0.015 | 0.175±0.022 | 0.164±0.010 | 0.231±0.041 | 0.209±0.077 | 0.200±0.025 | 0.239±0.030 | 0.216±0.012 | ||
| Monoexp | 751±62 | 1121±41 | 694±91 | 712±91 | 895±94 | 805±153 | 1265±75 | 1122±44 | 1065±90 | 792±96 | 791±60 | 795±29 | 888±24 | |
| 101±4 | 87±6 | 115±7 | 114±11 | 89±8 | 98±12 | 95±4 | 88±4 | 83±6 | 101±8 | 84±3 | 76±2 | 78±3 | ||
| 735±33 | 784±27 | 803±47 | 833±35 | 744±89 | 739±50 | 955±75 | 789±59 | 689±34 | 737±65 | 623±28 | 584±33 | 650±43 | ||
Relative difference of each estimated parameter in each anatomical area in the CJD + group compared to healthy controls.
| Differences in CJD + | ACC | PreCu | SFG | aMFG | STG | ITG | SPL | IPL | Occ | Hip | Cau | aPut | DMTh | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biexp | -14%*** | -5%* | -15%* | -16%** | + 11%* | + 23%** | -7% | + 7% | + 5% | -11%* | -9%** | -8%*** | -5%* | |
| + 36%*** | + 19%*** | + 44%** | + 41%*** | + 23%*** | + 8% | + 12%* | + 17%*** | + 31% | + 22%** | + 31%*** | + 28%*** | + 23%*** | ||
| + 17% | -24%*** | -21%** | -24%*** | -23% | -2% | -34%*** | -3% | -7% | -8% | -1% | -16%** | + 4% | ||
| -9% | -52%*** | -56%*** | -53%*** | -45%** | -26% | -52%*** | -34%** | -38%*** | -19% | + 81% | + 41% | + 28% | ||
| -6% | + 23%*** | + 27%*** | + 30%*** | + 9% | + 3% | + 14%** | + 8%* | -5% | -3% | -10%* | -5% | -9%* | ||
| Restricted | -13%** | + 3% | -13%* | -14%* | + 18%*** | + 29%** | + 3% | + 14%** | + 22% | -9%* | -9%** | -6%*** | + 1% | |
| + 32%*** | + 9%** | + 37%** | + 36%*** | + 13%** | + 2% | + 2% | + 9%** | + 12% | + 16%*** | + 29%*** | + 25%*** | + 15%*** | ||
| + 4% | -4% | 0% | -3% | + 3% | + 8% | -13% | + 13%* | -57% | + 13% | -10%* | -17%*** | -1% | ||
| + 27%** | + 89%*** | + 24%* | + 18%** | + 53%*** | + 48%** | + 96%** | + 76%*** | + 158%* | + 33% | + 14%* | + 17%** | + 58%*** | ||
| Monoexp | -18%*** | -9%*** | -20%** | -20%** | + 6% | + 15%* | -8% | 0 | -1% | -15%* | -12%*** | -10%*** | -12%*** | |
| + 46%*** | + 25%*** | + 61%** | + 54%*** | + 29%*** | + 13%* | + 15%* | + 24%*** | + 40% | + 29%** | + 35%*** | + 30%*** | + 29%*** | ||
| -12%** | -21%*** | -17%*** | -15%*** | -23%*** | -14%** | -27%*** | -15%** | -29%* | -15%* | -19%*** | -26%*** | -22%*** | ||
| Nr of ROIs | 17 | 19 | 8 | 11 | 13 | 13 | 10 | 15 | 3 | 9 | 17 | 16 | 14 | |
*p<0.05, **p<0.01, ***p<0.001
Relative difference of each estimated parameter in each anatomical area in the CJD- group compared to healthy controls.
| Differences in CJD- | ACC | PreCu | SFG | aMFG | STG | ITG | SPL | IPL | Occ | Hip | Cau | aPut | DMTh | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biexp | -17%* | + 11% | -7% | -12%* | + 7% | + 18%* | -16%*** | + 1% | + 13%** | -11%** | -5%* | -7%** | + 3% | |
| + 22%*** | + 1% | + 12%** | + 15%** | -2% | -3% | 0% | + 3% | + 7% | + 12%*** | + 15%* | + 13%*** | + 5% | ||
| + 10% | + 11% | -6% | + 11% | -23% | -13% | -19%* | + 27%** | + 13%* | + 21% | + 29% | + 9% | + 1% | ||
| -11% | -8% | -27%* | -16% | -35%* | -26% | -21%* | + 14% | + 2% | + 111%* | + 154% | + 5% | + 15% | ||
| 0% | + 13% | + 19%** | + 11% | + 17%* | + 7% | + 6% | -3% | 0% | -18%* | -12% | -2% | -1% | ||
| Restricted | -17%** | + 15% | -7% | -12%* | + 8% | + 20%* | -16%*** | 0% | + 23%*** | -12%*** | -7%* | -6%* | + 6%* | |
| + 22%*** | -2% | + 12%** | + 15%** | -3% | -5% | + 1% | + 3% | -1% | + 13%*** | + 17% | + 12%*** | + 3% | ||
| + 1% | + 24% | + 5% | + 6% | -5% | -4% | -13%* | + 18%* | + 24%* | 0% | + 7% | + 5% | + 3% | ||
| + 3% | + 25% | + 3% | + 5% | + 5% | + 19%* | + 2% | + 5% | + 56%*** | + 5% | + 2% | + 9% | + 17%* | ||
| Monoexp | -18%** | + 8% | -8% | -14%** | + 7% | + 14%* | -14%** | -2% | + 10%** | -13%* | -9%* | -10%** | + 2% | |
| + 24%*** | + 3% | + 15%** | + 18%** | -2% | -1% | + 4% | + 10% | + 15%* | + 19%** | + 19% | + 16%** | + 6% | ||
| -2% | + 13% | 0% | 0% | -3% | -12% | -13%** | + 12%* | + 5% | + 1% | 0% | -7% | -3% | ||
| Nr of ROIs | 3 | 1 | 12 | 9 | 7 | 7 | 10 | 5 | 17 | 11 | 3 | 4 | 6 | |
*p<0.05, **p<0.01, ***p<0.001. ^In ACC no change is significant because there is just one sample in the CJD- group
Relative difference of each estimated parameter in each anatomical area in the RPE group compared to healthy controls.
| Differences in RPE | ACC | PreCu | SFG | aMFG | STG | ITG | SPL | IPL | Occ | Hip | Cau | aPut | DMTh | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biexp | -11%** | + 3% | -7% | -11%* | -2% | + 25%* | -3% | + 16%** | + 2% | -3% | -4% | -8%* | -4% | |
| + 11%** | + 3% | + 15%* | + 5% | + 1% | -8% | -2% | + 2% | + 3% | + 7%* | + 1% | + 2% | + 3% | ||
| + 31%* | -6% | + 9% | -13% | -22% | + 2% | -19%** | -3% | -2% | -15% | + 30%* | + 18% | -6% | ||
| + 19% | -24%* | -13% | -33%* | -35% | -9% | -21%** | -17% | -15% | -16% | + 1% | -78% | -95% | ||
| -8% | + 25%** | + 19% | + 26%* | + 17%* | + 11% | + 14%* | + 18%** | + 9% | + 3% | -5% | -2% | + 6% | ||
| Restricted | -12%** | + 5% | -6% | -11%* | -2% | + 25%* | -1% | + 17%** | + 2% | -4% | -4% | -7%* | -2% | |
| + 11%** | + 1% | + 15%* | + 5% | + 1% | -8% | -2% | + 1% | + 3% | + 8%* | + 0% | + 2% | + 1% | ||
| + 18%** | + 18%* | + 20%*** | + 5% | -3% | + 11%* | -2% | + 10%** | + 5% | -3% | + 30%* | + 23%* | + 4% | ||
| + 12%** | + 9% | + 1% | + 4% | -3% | -1% | + 2% | -2% | -9% | -10% | + 25%* | + 16%* | + 8% | ||
| Monoexp | -14%** | + 1% | -8% | -11%* | -1% | + 23%* | -1% | + 15%** | + 4% | -3% | -10%* | -13%* | -6% | |
| + 13%** | + 4% | + 18%* | + 5% | + 0% | -7% | -3% | + 2% | + 3% | + 8% | + 4% | + 5% | + 4% | ||
| + 8% | + 12%* | + 16%*** | + 1% | -1% | + 9%* | -1% | + 11%** | + 10%** | + 5% | + 4% | + 0% | -5% | ||
*p<0.05, **p<0.01, ***p<0.001
Relative difference of each estimated parameter in each anatomical area in the GSS group compared to healthy controls.
| Differences in GSS | ACC | PreCu | SFG | aMFG | STG | ITG | SPL | IPL | Occ | Hip | Cau | aPut | DMTh | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biexp | -21%*** | -3% | -19%** | -20%** | + 9% | + 22%* | -4% | + 10% | + 4% | -2% | -10%** | -18%** | + 3% | |
| + 4% | -5% | + 3% | + 2% | -5% | -14%* | -9%*** | -4% | -3% | -2% | + 2% | + 5%* | -4%* | ||
| -21%** | + 9% | -14% | -14% | -16% | + 24%* | -15% | -2% | + 2% | -34% | + 36% | -1% | + 30% | ||
| -59%* | + 12% | -14% | -11% | + 16% | + 51%* | -23% | -18% | -5% | -55% | + 250% | -100% | + 243% | ||
| + 20%** | -10% | + 11% | + 8% | -6% | -22%* | + 8% | + 11% | + 4% | + 8% | -19% | -1% | -19% | ||
| Restricted | -20%*** | -3% | -18%** | -19%** | + 9% | + 21%* | + 1% | + 13% | + 4% | -3% | -11%** | -17%** | + 2% | |
| + 3% | -5% | + 3% | + 2% | -5% | -14%* | -12%*** | -6%* | -3% | 0% | + 3% | + 4%* | -4%* | ||
| -5% | + 3% | -1% | -7%* | -11% | + 4% | + 1% | + 11%** | + 5% | -22% | + 2% | + 5% | + 1% | ||
| + 3% | + 5% | + 5% | + 2% | -14%* | -1% | + 39%*** | + 27% | -3% | -20% | -3% | + 20% | -3% | ||
| Monoexp | -18%** | -3% | -17%** | -17%** | + 13%* | + 21%* | -4% | + 8% | + 5% | + 3% | -9%** | -18%** | + 3%* | |
| + 2% | -5% | + 1% | 0% | -8% | -15%* | -10%*** | -3% | -3% | -5% | + 2% | + 5%* | -5%* | ||
| -2% | + 1% | + 0% | -4% | + 1% | + 5% | -8%* | + 2% | + 7% | -6% | + 5% | -5% | + 6% | ||
*p<0.05, **p<0.01, ***p<0.001